Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.44 |
| ▸ | YAP1 | P46937 | 3/20 | 0.43 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2227744 | 0.90 | HTR6 (0.48) | HTR6GPR119YAP1PRMT5JAK2 | |
| SCHEMBL2226304 | 0.87 | HTR6 (0.43) | HTR6GPR119SFRP1JAK2 | |
| SCHEMBL16551431 | 0.84 | HTR6 (0.47) | HTR6GPR119SFRP1 | |
| SCHEMBL2352934 | 0.82 | HTR6 (0.51) | HTR6GPR119SFRP1 | |
| SCHEMBL2228730 | 0.80 | HTR6 (0.47) | HTR6GPR119SFRP1JAK2 | |
| SCHEMBL12518697 | 0.80 | HTR6 (0.45) | HTR6GPR119 | |
| SCHEMBL16550792 | 0.79 | HTR6 (0.40) | HTR6GPR119SFRP1JAK2 | |
| SCHEMBL13507077 | 0.78 | HTR6 (0.42) | HTR6GPR119SFRP1 | |
| SCHEMBL2223135 | 0.78 | STS (0.53) | HTR6GPR119SFRP1JAK2 | |
| SCHEMBL3895019 | 0.77 | HRH3 (0.50) | GPR119YAP1GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516445-B1 | TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CEPHALON INC (US) | 2015-03-11 | — | — | EP | disclosed |
| EP-2516445-B1 | TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CEPHALON INC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8765779-B2 | Tricyclic derivatives and their pharmaceutical use and compositions | CEPHALON, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765779-B2 | Tricyclic derivatives and their pharmaceutical use and compositions | CEPHALON, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765779-B2 | Tricyclic derivatives and their pharmaceutical use and compositions | CEPHALON, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120295882-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CEPHALON, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295882-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CEPHALON, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295882-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CEPHALON, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2516445-A2 | TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | Cephalon, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011087712-A2 | TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CEPHALON, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011087712-A2 | TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | CEPHALON, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295882-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CYP3A43, CYP3A7, CYP2C19 | HTR6 537/4885GPR119 1673/4885YAP1 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.